Ovarian Cancer: Post-Relapse Survival and Prognostic Factors

Ai Miyoshi, Serika Kanao, Hirokazu Naoi, Hirofumi Otsuka, Takeshi Yokoi

Abstract


Background: Patients with relapsing ovarian cancer have a particularly poor prognosis, it is thus important for oncology consultants to anticipate the patient’s adverse prognosis and to select an optimum treatment plan. We report here our retrospective review of the treatment outcomes of the post-relapse survival (PRS) for ovarian cancer and the different prognostic factors for relapsing patients.

Methods: Totally 242 patients with ovarian cancer were admitted to our institution. All underwent surgery, and all achieved complete remission of their primary disease. Of the 242 patients, 48 were subsequently diagnosed with a recurrence. We retrospectively reviewed their initial FIGO staging, the histology of their tumors, the treatment-free interval (TFI), the number of recurrent lesions, the treatment for the recurrence (whether treatment included surgery, radiotherapy or chemotherapy), and the number of chemotherapy regimens applied for treatment of the recurrence.

Results: The median age of the 48 relapse patients was 59 years (range 34 - 83); the median follow-up period was 40 months (range 4 - 103). The multivariate Cox proportional hazards model demonstrated that having a mucinous histology (P = 0.029), having a TFI of less than 6 months (P = 0.0002), having a solitary recurrent lesion (P = 0.011), and no chemotherapy (P = 0.007) were independent risk factors associated with PRS. The number of recurrent lesions, multimodal treatment for recurrence, the number of chemotherapy regimens used for treatment, and use of bevacizumab were not independent factors for PRS.

Conclusions: In regards to recurrent ovarian cancer, after achieving complete surgical remission of the primary disease, having a mucinous adenocarcinoma histology and/or a TFI of less than 6 months worsened the prognosis for the patient. Having a solitary recurrent lesion was a better prognostic factor regardless of whether or not they received surgical treatment. Chemotherapy could improve PRS, if the performance status (PS) of the patient allows her to receive chemotherapy, and if she is desirous of the attempt to extend her life.




J Clin Gynecol Obstet. 2018;7(2):31-36
doi: https://doi.org/10.14740/jcgo488w


Keywords


Post-relapse survival; Ovarian cancer; Prognostic factor

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Clinical Gynecology and Obstetrics, quarterly, ISSN 1927-1271 (print), 1927-128X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal, the authors retain the copyright, the journal is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International
License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jcgo.org   editorial contact: editor@jcgo.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!